Table 2.
Single-reagents that target TAMs for cancer treatments.
| Treatment | Type of study | References | |
|---|---|---|---|
| Targeting macrophage infiltration | |||
| Anti-CSF1/CSF1R antibody | In vivo; mice; breast, osteosarcoma, pancreatic, glioma cancer | 42–44,46,64 | |
| PLX3397 (CSF1R inhibitor) | Phase 1 clinical trial; solid, pancreatic cancers | 47,64 | |
| Emactuzumab (anti-CSF1R antibody) | Phase 1 clinical trial; soft tissue tumors | 48 | |
| Siltuximab (anti-IL-6 antibody) | Phase 1, 2 clinical trials; ovarian, prostate, renal cell, advanced solid cancer | 53–56 | |
| Carlumab (anti-CCL2 antibody) | Phase 1, 2 clinical trials; solid, prostate cancer | 51,52 | |
| Anti-CCL2 antibody | In vivo; mice; breast, glioma, prostate cancer | 45,126,127 | |
| CCL2 siRNA | In vivo; mice; breast cancer | 125 | |
| Treatment | Type of study | Functions | References |
| Targeting macrophage polarization/activation | |||
| P. aeruginosa mannose-sensitive hemagglutinin | Ex vivo | M1 promotion | 58 |
| Iron oxide nanoparticles | In vivo; mice; adenocarcinoma | M1 promotion | 59 |
| miRNAs | In vivo; mice; lung, liver cancer | M2 inhibition | 61,62 |
| STAT3 inhibition | Ex vivo; in vivo; mice; sarcoma | M2 inhibition | 174,175 |
| CD40 agonist | Phase 1 clinical trials; solid tumors and diffuse large B-cell lymphoma | M1 promotion | 66,176 |
| Dacetuzumab (anti-CD40 antibody) | Phase 1 clinical trial; non-Hodgkin’s lymphoma | M1 promotion | 67 |
| CD870,873 (anti-CD40 antibody) | Phase 1 clinical trials; pancreatic ductal adenocarcinoma; solid tumors | M1 promotion | 68–70 |
| β-glucan | Phase 1 clinical trials; pancreatic ductal adenocarcinoma; solid tumors | M1 promotion | 177 |
| Trabectedin (anti-tumor reagent) | In vivo; mice; sarcoma, ovarian cancer Phase 3 clinical trial; soft tissue sacorma |
M2 inhibition | 73–75 |